short term treatment acromegali somatostatin analog first double-blind placebo-control studi effect sever studi somatostatin analog sm GH hypersecret doubl blind placebo-control studi find result random doubl clinic trial octreotid patient acromegali drug sc initi dose microgram microgram day microgram GH level mean valu observ hourli interv insulin-lik growth factor-i igf-i level octreotid treatment respons reduct basal mean GH level signific reduct patient good correl reduct GH igf-i level main side-effect gastrointestin spontan variat daili mean GH igf-i level placebo group GH igf-i level day patient octreotid occurr GH rise administr time desir octreotid patient 